The Cell & Gene Therapy Manufacturing Pathway: Part 3
Supported by GE Healthcare
Innovation and Excellence in ATMP Manufacturing
PART 3: Understanding your product and processes
Guest editors: Greg Russotti, Stephen Ward & Peter Zandstra
As more cell and gene therapies move towards the clinic, manufacturers are faced with a number of challenges pertaining to the move from clinical-stage bioprocesing to commercial-scale manufacturing. What are the implications of making process changes as you move towards commercialization and how can you control for these variables and the potential risks they introduce? This spotlight addresses these critical questions including.